Skip to main content

Clinical Trials Using Decitabine

Review the clinical trials studying decitabine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 32

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Status: Active
Location: 13 locations
Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome
Status: Active
Location: 6 locations
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Status: Active
Location: 10 locations
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Status: Active
Location: 5 locations
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
Status: Active
Location: 3 locations
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
Status: Active
Location: 3 locations
Low-Dose Decitabine and Venetoclax for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia
Status: Active
Location: 2 locations
Decitabine in Combination with Filgrastim Post-Hematopoietic Stem Cell Transplant in Preventing Relapse of Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Related Myeloid Malignancies in Pediatric and Young Adult Patients
Status: Active
Location: 2 locations
ASTX727 for the Treatment of Advanced, Unresectable, or Metastatic Solid Tumors
Status: Active
Location: 2 locations
Pembrolizumab and Decitabine with or without Venetoclax in Treating Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
Status: Active
Location: 2 locations
Discontinuation of Hypomethylating Agent and Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Who Have Achieved Negative Measurable Residual Disease
Status: Active
Location: 2 locations
Decitabine with Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Olutasidenib in Combination with Hypomethylation Therapy for the Treatment of IDH1-Mutated Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Myeloproliferative Neoplasms
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Calaspargase Pegol-mknl and Decitabine Combined with Venetoclax for the Treatment of Pediatric, Adolescent, and Young Adult Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cladribine, Cytarabine, and Decitabine With or Without Venetoclax and Gilteritinib in Treating Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, Clonal Cytopenia of Undetermined Significance and Chronic Myelomonocytic Leukemia
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Decitabine and Venetoclax for Maintenance Treatment in Patients with AML and MDS After Donor Stem Cell Transplant
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Decitabine and Venetoclax in Combination with Olutasidenib for the Treatment of Patients with Newly Diagnosed, Recurrent or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Quizartinib, Decitabine, and Venetoclax in Treating Patients with Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
PRAME-TCR-NK Cells with Lymphodepleting Chemotherapy for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Immune System Cells for the Treatment of Relapse or Refractory Hematological Cancers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy (Decitabine in Combination with FLAG-Ida) and Total-Body Irradiation followed by Donor Stem Cell Transplant for the Treatment of Adults with Myeloid Malignancies at High Risk of Relapse
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Avapritinib in Combination with Decitabine for the Treatment of Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida